Sun Pharma’s Q2 Results: Sun Pharma has demonstrated robust financial health in the second quarter of fiscal year 2025, with significant gains in net profit and steady growth across its key markets. The company’s strategic expansions and operational enhancements continue to yield positive results, underlining its strong position in the global pharmaceutical landscape.
Sun Pharma Q2 FY25 Earnings Overview
Sun Pharma reported strong Q2 results with a net profit of ₹3,040 crore, up 28% YoY. The company’s total revenue also increased by 9%, reaching ₹13,291.39 crore, driven by robust sales across all regions.
US Market Performance
In the US, Sun Pharma’s formulation sales hit US$ 517 million, a 20.3% increase from last year, making up 33% of total sales. This growth reflects the company’s expanding influence in the North American market.
Also Read: RIL Bonus Issue Doubles Shares – Uncover Details!
India Formulations Growth
Sales of formulations in India rose to ₹4,265.2 crore, up 11% YoY. This segment accounted for 32% of the total consolidated sales, indicating strong domestic demand.
Emerging Markets and ROW Analysis
Emerging markets saw a modest growth of 3.2%, with sales of US$ 293 million. However, the Rest of World (ROW) markets experienced a slight decline of 3.5%, underscoring varied regional dynamics.
Also Read: Discover Tata Tech’s Q2 Results, Post 2023 IPO Surge – Read!
Research and Development Investments
Sun Pharma’s commitment to innovation is evident in its R&D spending of ₹792.9 crore for the quarter, maintaining a consistent investment of around 6% of total sales.
Active pharmaceutical Ingredients (API) Update
The API segment posted revenues of ₹533.8 crore, up 7.4% from last year. This growth supports Sun Pharma’s strategy of vertical integration and ensuring supply chain continuity for its formulation business.
